Cover Image
市場調查報告書

PCI Biotech AS:產品平台分析

PCI Biotech AS - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321349
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
PCI Biotech AS:產品平台分析 PCI Biotech AS - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 34 Pages
簡介

PCI Biotech AS 是活用於基因治療和蛋白質療法,寡核苷酸治療,化療及奈米醫療等商品化光化學物質藥的送達技術的生物科技企業。該公司還在癌症的治療中採取誘導免疫機制的方法。

本報告提供PCI Biotech AS 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

PCI Biotech AS的基本資料

  • PCI Biotech AS概要
  • 主要資訊
  • 企業資料

PCI Biotech AS :R&D概要

  • 主要的治療範圍

PCI Biotech AS :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

PCI Biotech AS :開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式

PCI Biotech AS :藥物簡介

  • bleomycin sulfate
  • gemcitabine hydrochloride
  • (TPCS2a + ADC)
  • (TPCS2a + siRNA)
  • Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma
  • TPCS-2A

PCI Biotech AS :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

PCI Biotech AS :最近的開發平台趨勢

PCI Biotech AS :暫停中的計劃

PCI Biotech AS :開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • (amphinex + epirubicin hydrochloride)

PCI Biotech AS :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07307CDB

Summary

Global Markets Direct's, 'PCI Biotech AS - Product Pipeline Review - 2015', provides an overview of the PCI Biotech AS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of PCI Biotech AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of PCI Biotech AS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of PCI Biotech AS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the PCI Biotech AS's pipeline products

Reasons to buy

  • Evaluate PCI Biotech AS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of PCI Biotech AS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the PCI Biotech AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of PCI Biotech AS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of PCI Biotech AS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of PCI Biotech AS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • PCI Biotech AS Snapshot
    • PCI Biotech AS Overview
    • Key Information
    • Key Facts
  • PCI Biotech AS - Research and Development Overview
    • Key Therapeutic Areas
  • PCI Biotech AS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • PCI Biotech AS - Pipeline Products Glance
    • PCI Biotech AS - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • PCI Biotech AS - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • PCI Biotech AS - Drug Profiles
    • bleomycin sulfate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gemcitabine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (TPCS2a + ADC)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (TPCS2a + mRNA)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (TPCS2a + siRNA)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TPCS-2A
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • PCI Biotech AS - Pipeline Analysis
    • PCI Biotech AS - Pipeline Products by Target
    • PCI Biotech AS - Pipeline Products by Route of Administration
    • PCI Biotech AS - Pipeline Products by Molecule Type
    • PCI Biotech AS - Pipeline Products by Mechanism of Action
  • PCI Biotech AS - Recent Pipeline Updates
  • PCI Biotech AS - Dormant Projects
  • PCI Biotech AS - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • (amphinex + epirubicin hydrochloride)
  • PCI Biotech AS - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • PCI Biotech AS, Key Information
  • PCI Biotech AS, Key Facts
  • PCI Biotech AS - Pipeline by Indication, 2015
  • PCI Biotech AS - Pipeline by Stage of Development, 2015
  • PCI Biotech AS - Monotherapy Products in Pipeline, 2015
  • PCI Biotech AS - Combination Treatment Modalities in Pipeline, 2015
  • PCI Biotech AS - Phase II, 2015
  • PCI Biotech AS - Phase I, 2015
  • PCI Biotech AS - Preclinical, 2015
  • PCI Biotech AS - Pipeline by Target, 2015
  • PCI Biotech AS - Pipeline by Route of Administration, 2015
  • PCI Biotech AS - Pipeline by Molecule Type, 2015
  • PCI Biotech AS - Pipeline Products by Mechanism of Action, 2015
  • PCI Biotech AS - Recent Pipeline Updates, 2015
  • PCI Biotech AS - Dormant Developmental Projects,2015
  • PCI Biotech AS - Discontinued Pipeline Products, 2015

List of Figures

  • PCI Biotech AS - Pipeline by Top 10 Indication, 2015
  • PCI Biotech AS - Pipeline by Stage of Development, 2015
  • PCI Biotech AS - Monotherapy Products in Pipeline, 2015
  • PCI Biotech AS - Pipeline by Top 10 Target, 2015
  • PCI Biotech AS - Pipeline by Top 10 Route of Administration, 2015
  • PCI Biotech AS - Pipeline by Top 10 Molecule Type, 2015
  • PCI Biotech AS - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top